Literature DB >> 11792853

Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.

Kusumam Joseph1, Baby G Tholanikunnel, Allen P Kaplan.   

Abstract

Bradykinin is a major mediator of swelling in C1 inhibitor deficiency as well as the angioedema seen with ACE inhibitors and may contribute to bronchial hyperreactivity in asthma. Formation of bradykinin occurs in the fluid phase and along cell surfaces requiring interaction of factor XII, prekallikrein, and high M(r) kininogen (HK). Recent data suggest that activation of the kinin-forming cascade can occur on the surface of endothelial cells, even in the absence of factor XII. We sought to further define this factor XII-independent mechanism of kinin formation. Both cytosolic and membrane fractions from endothelial cells possessed the ability to catalyze prekallikrein conversion to kallikrein, and activation depended on the presence of HK and zinc ion. We fractionated the cytosol by ion exchange chromatography and affinity chromatography by using corn trypsin inhibitor as ligand. The fractions with peak activity were subjected to SDS gel electrophoresis and ligand blot with biotinylated corn trypsin inhibitor, and positive bands were sequenced. Heat shock protein 90 (Hsp90) was identified as the protein responsible for zinc-dependent prekallikrein activation in the presence of HK. Zinc-dependent activation of the prekallikrein-HK complex also depended on addition of either alpha and beta isoforms of Hsp90 and the activation on endothelial cells was inhibited on addition of polyclonal Ab to Hsp90 in a dose-dependent manner. Although the mechanism by which Hsp90 activates the kinin-forming cascade is not understood, this protein represents the cellular contribution to the reaction and may become the dominant mechanism in pathologic circumstances in which Hsp90 is highly expressed or secreted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792853      PMCID: PMC117402          DOI: 10.1073/pnas.022626899

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Mapping of functional domains of human high molecular weight and low molecular weight kininogens using murine monoclonal antibodies.

Authors:  H Ishiguro; S Higashiyama; I Ohkubo; M Sasaki
Journal:  Biochemistry       Date:  1987-11-03       Impact factor: 3.162

2.  Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells.

Authors:  D F Liao; Z G Jin; A S Baas; G Daum; S P Gygi; R Aebersold; B C Berk
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

3.  Human neutrophils contain and bind high molecular weight kininogen.

Authors:  E J Gustafson; A H Schmaier; Y T Wachtfogel; N Kaufman; U Kucich; R W Colman
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

4.  High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage.

Authors:  F J Meloni; E J Gustafson; A H Schmaier
Journal:  Blood       Date:  1992-03-01       Impact factor: 22.113

5.  Mutations in Hsp83 and cdc37 impair signaling by the sevenless receptor tyrosine kinase in Drosophila.

Authors:  T Cutforth; G M Rubin
Journal:  Cell       Date:  1994-07-01       Impact factor: 41.582

6.  Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains.

Authors:  S R Reddigari; P Kuna; G Miragliotta; Y Shibayama; K Nishikawa; A P Kaplan
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

7.  The binding of high molecular weight kininogen to cultured human endothelial cells.

Authors:  F van Iwaarden; P G de Groot; B N Bouma
Journal:  J Biol Chem       Date:  1988-04-05       Impact factor: 5.157

8.  Mutational analysis of Hsp90 function: interactions with a steroid receptor and a protein kinase.

Authors:  D F Nathan; S Lindquist
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

9.  Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells.

Authors:  S R Reddigari; Y Shibayama; T Brunnée; A P Kaplan
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

10.  A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90.

Authors:  R Aligue; H Akhavan-Niak; P Russell
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

View more
  40 in total

1.  Plasma kallikrein and diabetic macular edema.

Authors:  Edward P Feener
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 2.  Therapeutic approaches in hereditary angioedema.

Authors:  Sabina Antonela Antoniu
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

3.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

4.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

5.  Adjunctive immunotherapy in combination with lipid-associated amphotericin B for the treatment of invasive candidiasis.

Authors:  Stanley Chapman
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

Review 6.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

Review 7.  Complement, Kinins, and Hereditary Angioedema: Mechanisms of Plasma Instability when C1 Inhibitor is Absent.

Authors:  Allen P Kaplan; Kusumam Joseph
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

Review 8.  New therapeutics in C1INH deficiency: a review of recent studies and advances.

Authors:  Neil Parikh; Marc A Riedl
Journal:  Curr Allergy Asthma Rep       Date:  2011-08       Impact factor: 4.806

Review 9.  The initiation and effects of plasma contact activation: an overview.

Authors:  Lisha Lin; Mingyi Wu; Jinhua Zhao
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 10.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.